Plus Therapeutics FY2025 net loss $22.4M; cash $13.1M, outlines 2026 milestones for REYOBIQ and CNSide

PLUS THERAPEUTICS, INC.

Net loss $22.4M ($0.29/shr) vs $13.0M ($1.95/shr) in 2024; operating loss $15.3M vs $14.7M.
Cash and investments $13.1M at Dec 31, 2025 (up from $3.6M); raised $15M gross in upsized public offering.
CNSide lab licensed in 49 states; coverage agreements with Humana and UnitedHealthcare reach ~67M lives.
2026 milestones: REYOBIQ Phase 2 LM data Q3 2026, GBM data Q4; CNSide target >1,250 annual test orders, breakeven by 2027.
Secured AMA Category III CPT code for convection-enhanced delivery with REYOBIQ, unlocking market access.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-104218
form_type: 8-K
ticker: PSTV
cik: 0001095981
company_name: PLUS THERAPEUTICS, INC.
filed_at: 2026-03-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:34.532926+00:00
generated_at: 2026-05-15T12:53:56.031051+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-104218
json_url: https://secwatch.observer/filing/0001193125-26-104218.json
markdown_url: https://secwatch.observer/filing/0001193125-26-104218.md
text_url: https://secwatch.observer/filing/0001193125-26-104218.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526104218/0001193125-26-104218-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526104218/pstv-20260312.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-104218

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.